Priorities

null
This Pill Can Stop HIV – But Why Is No One Taking It?

This Pill Can Stop HIV – But Why Is No One Taking It?

by The Daily Eye Team August 16 2014, 8:11 am Estimated Reading Time: 1 min, 2 secs

The drug that could end the HIV pandemic is already here. Branded Truvada, this pre-exposure prophylaxis (PrEP) prevents HIV infection by blocking the virus’s ability to replicate. “It’s a big deal,” says Robert Grant, a leading HIV/AIDS investigator at the University of California, San Francisco. “It’s an opportunity for uninfected people to proactively protect themselves.” Approximately 50,000 Americans will develop HIV this year. But since Truvada was approved as a PrEP in 2012, only 10,000 patients—or two percent of the 500,000 Americans identified as “high risk” by the Centers for Disease Control and Prevention (CDC)—have gotten a prescription for it.

Critics have vocalized concerns about side effects. “People have memories of what it was like to be treated with very high doses of drugs in the 1980s,” Grant says. “That lingers on even though HIV medication is much safer than it used to be.” In fact, Truvada has been used to help treat HIV for a decade. But, as with birth control in the 1960s, the concept of a pill regimen for safer sex was stigmatized, triggering a backlash against so-called “Truvada whores.”

Click Here To Read More



About Author


User avatar

Shantanu Ray Chaudhuri


Shantanu Ray Chaudhuri is a film buff and an editor. Books commissioned and edited by him have won the National Award for Best Book on Cinema twice and the inaugural MAMI (Mumbai Academy of Moving Images) Award for Best Writing on Cinema. In 2017, he was named Editor of the Year by the apex publishing body, Publishing Next. He has written for the online magazine Film Companion. He is a consultant, writer and editor for the newly launched film website Cinemaazi.com. He is the author of two books: Whims – A Book of Poems (published by Writers Workshop) and Icons from Bollywood (published by Penguin/Puffin).    


Disclaimer: The views and opinions expressed in this article are those of the authors and do not necessarily reflect the official policy or position of thedailyeye.info. The writers are solely responsible for any claims arising out of the contents of this article.